The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Maria Karlsson Osipova, DNB Carnegie . Maria.Karlsson.Osipova@dnbcarnegie.se

Annual Report

  December 2, 2025

Company Presentation

 March 26, 2026
Download PDF

CEO Comments

Read More
  Quarterly Report 3, June 24, 2026

The past quarter has been one of the most challenging periods in Diamyd Medical’s history. Following the pre-specified interim analysis of our confirmatory Phase 3 trial DIAGNODE-3, we announced March 27, that the study yielded results that were totally unexpected and not aligned with prior retrospective or prospective data. Subsequent evaluation confirmed that the pre-specified futility criteria had been met, leading to the difficult but...

The last quarter has been particularly eventful and the discontinuation of DIAGNODE-3 was hugely disappointing. Against that, progress is being made at our manufacturing unit in Umeå, and intense activities are ongoing to secure long term shareholder value for Diamyd Medical’s shareholders.

Calendar

  
October 7, 2026
Year-end Report
Year-end Report 2025/2026
December 3, 2026
Annual General Meeting
Annual General Meeting 2026

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd Medical team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
 

Diamyd Medical

Developing precision medicine therapies for the prevention and treatment of autoimmune diabetes

 

Ten largest shareholders as of March 31, 2026

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 16 831 119 10.86 9.02
Lindkvist, Bertil 9 150 000 5.90 4.91
Essen-Möller, Anders * 1 235 620 5 297 192 4.22 9.46
Nordnet Pensionsförsäkring 6 510 417 4.20 3.49
Perceptive Advisors LLC 4 134 250 2.67 2.22
Vestal Point Capital LP 2 111 386 1.36 1.13
RA Capital Management LP 2 051 760 1.32 1.10
Point 72 Asset Management 2 022 864 1.31 1.08
Vivo Capital 1 378 000 0.89 0.74
Essen-Möller, Maria-Teresa 400 000 963 998 0.88 2.66
Remaining shareholders 1 867 500 101 030 394 66.39 64.18
Total 3 503 120 151 481 380 100.0 100.0
* Holdings include 2 178 152 class B-shares in an endowment policy and 100 000 class A-shares in a consulting company.

Order GAD for preclinical research

ORDER

Annual Report

  December 2, 2025
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research